Invest in Viz.ai

Organizations employing Viz.ai technology have experienced accelerated decision-making by their care teams, enabling healthcare providers to achieve improved outcomes and heightened productivity. Additionally, users have seen a reduction in resource utilization and an enhancement in hospital financial performance.

Data from patients at Viz.ai’s partner hospitals is fed into the platform's AI algorithm, which has been trained on images of neurological and cardiovascular disorders. This training enables the algorithm to identify patterns and assist in making diagnoses.

Going beyond mere detection, the platform proactively notifies the closest specialist, who could be in a different ward or even a neighboring hospital, through a secure smartphone network. This approach is designed to expedite the treatment process, ensuring timely medical intervention.

Viz.ai One is an AI-powered care coordination solution designed to revolutionize the way patient care is delivered. Now, any team, with the clinically-validated Viz.ai One solution, can help ensure patients receive lifelong care and the treatments they need, when and where they need it–before it’s too late.

The Viz.ai One suite includes several products: Neuro, Vascular, Cardio, Radiology, and Trauma.

Viz Neuro is a comprehensive suite of AI-powered solutions designed to improve neurovascular outcomes: (1) Viz LVO is the leader in AI-powered stroke care coordination, (2) Viz CTP is an AI-powered solution designed to evaluate computed tomography (CT) perfusion imagin, (3) Viz ICH is an AI-powered solution for the detection and quantification of intracerebral hemorrhage (ICH), (4) Viz Aneurysm is an AI-powered solution that can automatically detect and triage suspected aneurysms, (5) Viz Subdural is an AI-powered solution for subdural care coordination.

Viz Vascular is a comprehensive suite of AI-powered vascular workflow solutions. Viz.ai optimizes workflow and improves efficiency, enabling vascular teams to deliver faster and more effective patient care.

Viz PE is an AI-powered solution for the detection of suspected pulmonary embolism (PE).

Viz Aortic is an AI-powered solution for the detection of suspected abdominal aortic aneurysm (AAA) and aortic dissection.

Viz Cardio is an all-in-one cardiovascular solution for cardiologists. The Cardio Suite helps identify patients with targeted cardiovascular disease and ensures the right clinician is alerted and involved.

Viz Radiology provides image analysis to aid radiologists by reducing turnaround time and increasing quality and efficiency by flagging potential indications in real time.

Viz radiology expedites patient diagnosis and treatment through a comprehensive suite of purpose-built AI-powered assist tools tailored for radiologists.

Viz Trauma is a comprehensive software solution tailored for trauma care providers to expedite patient care and improve outcomes.

Viz.ai makes money through a subscription-based model by charging hospitals for the use of its AI-powered disease detection and care coordination platform.

According to Forbes, Viz.ai’s annual recurring revenue (ARR) has been roughly doubling each year and is expected to reach $100 million in 2024, from $12 million in 2020. Viz.ai’s annual revenue is expected to be approximately $40 million in 2023 and approximately $60 million to $70 million in 2024. The company is not yet profitable.

Viz is expanding into generative AI which includes a pilot program with Mount Sinai and other hospitals. The initiative focuses on summarizing patients' medical records and extensively searching academic literature to uncover pertinent information that could potentially be overlooked.

Ultimately, Viz.ai’s CEO, Chris Mansi, hopes that the combination of image-based AI and generative AI will allow it to detect hundreds of diseases. In addition to neurology and cardiology, Viz.ai sees opportunities in oncology, for example in lung cancer, which is often missed on early X-rays.

Viz has also begun working with drug companies and medical device manufacturers. These companies are seeking methods to accelerate and streamline their product launches, a need that has grown in importance following changes in drug pricing introduced by the 2022 Inflation Recovery Act.

In March 2023, Viz.ai announced a multi-year agreement with Bristol Myers Squibb, a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and provider workflow software intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy.

In March 2023, Viz.ai announced it had received U.S. Food and Drug Administration (FDA) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA). Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected AAA.

In March 2023, Viz.ai was named one of Fierce Medtech’s “Fierce 15 Medtech Companies of 2022,” designating it as one of the most promising private medtech companies in the industry.

In April 2023, Viz.ai was named to the 2023 Forbes AI 50 list of the most promising private artificial intelligence (AI) startups globally. This is the 4th time Viz.ai has been recognized in the Forbes AI 50 list.

In August 2023, Viz.ai announced that it had received a De Novo approval from the U.S. Food and Drug Administration for its Viz HCM module, hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, creating a new regulatory category for cardiovascular machine learning-based notification software. The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb announced in March 2023. With the use of Viz HCM, which is integrated into the Viz.ai Platform, more patients with suspected HCM can be identified earlier using AI and triaged for diagnosis and further evaluation.

In October 2023, Goldman Sachs recognized Viz.ai CEO and Co-Founder Chris Mansi, as one of the Most Exceptional Entrepreneurs of 2023 at its Builders and Innovators Summit. Goldman Sachs selected Dr. Mansi from multiple industries to be honored at the two-day event.